title: The inflammasome and IL-1β: implications for the treatment of inflammatory diseases.
abstract: The bioactive form of IL-1β, a key immunoregulatory and proinflammatory cytokine, is produced by the inflammasome - a caspase-1 activating molecular platform - in response to selected danger-associated molecular patterns and pathogen-associated molecular patterns. Advances in understanding the role of IL-1β in inflammatory conditions has resulted in IL-1β becoming a therapeutic target for a number of inflammatory diseases beyond the rare monogenic autoinflammatory diseases characterized by aberrant inflammasome function and enhanced bioactive IL-1β production. In the monogenic autoinflammatory diseases known as cryopyrin-associated periodic syndromes, neutralization of IL-1β results in a rapid and sustained reduction in disease severity without severe side effects, which has consequently driven off-label applications of IL-1β-targeted therapy in other inflammatory diseases. This review summarizes inflammatory diseases for which accumulating evidence suggests a therapeutic potential for IL-1β antagonists.
authors: Department of Dermatology, University Hospital Zurich, Zurich 8091, Switzerland.
authors: Takashi
authors: T
authors: Satoh
authors: Atsushi
authors: A
authors: Otsuka
authors: Emmanuel
authors: E
authors: Contassot
authors: Lars E
authors: LE
authors: French
mesh_terms: D000818:Animals; D019138:Antibodies, Blocking / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D020170:Caspase 1 / Q000378:metabolism; D056587:Cryopyrin-Associated Periodic Syndromes / Q000276:immunology / Q000628:therapy*; D006801:Humans; D058847:Inflammasomes / Q000378:metabolism*; D007249:Inflammation / Q000276:immunology / Q000628:therapy*; D053590:Interleukin 1 Receptor Antagonist Protein / Q000627:therapeutic use; D053583:Interleukin-1beta / Q000378:metabolism*
chemical_list: D019138:Antibodies, Blocking; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D058847:Inflammasomes; D053590:Interleukin 1 Receptor Antagonist Protein; D053583:Interleukin-1beta; C541220:canakinumab; D020170:Caspase 1
keywords: IL-1β; anakinra; autoinflammatory disease; canakinumab; caspase-1; inflammasome; inflammation; rilonacept